TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been given a consensus rating of “Moderate Buy” by the six research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $40.67.

A number of equities analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Wednesday, January 15th. StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. upped their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. Finally, TD Cowen started coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $30.90 on Friday. The stock has a market cap of $4.81 billion, a price-to-earnings ratio of -308.97 and a beta of 2.26. The business has a fifty day moving average of $31.28 and a 200-day moving average of $27.21. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics has a fifty-two week low of $12.84 and a fifty-two week high of $36.84.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Institutional investors have recently made changes to their positions in the stock. Arizona State Retirement System increased its stake in shares of TG Therapeutics by 0.9% in the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock valued at $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. boosted its position in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 371 shares during the period. NBC Securities Inc. increased its holdings in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the period. Private Advisor Group LLC raised its stake in shares of TG Therapeutics by 3.9% during the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 542 shares in the last quarter. Finally, Brookstone Capital Management lifted its holdings in TG Therapeutics by 3.7% in the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 624 shares during the period. 58.58% of the stock is owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.